Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Rev. méd. Chile ; 137(9): 1209-1216, sep. 2009. tab, ilus
Article Dans Espagnol | LILACS | ID: lil-534025

Résumé

Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep-onset rapid eye movement (REM) sleep periods. It is now identified as a neurodegenerative disease because there is a massive loss of specific neurons in the brain. These neurons contain the neuropeptides hypocretin-1 and hypocretin-2, which are also known as orexin-A and orexin-B. Cerebrospinal fluid hypocretin-1 measurements are diagnostic for primary narcolepsy. The cause of neural loss could be autoinmune since most patients have the HLA DQB1*0602 alíele that predisposes to the disorders. The discovery of hypocretin deficiency is redefining the clinical entity of narcolepsy and offering novel diagnostic procedures. This article reviews the current understanding of narcolepsy and discusses the implications of hypocretin discovery (Rev Méd Chile 2009; 137:1209-16).


Sujets)
Humains , Narcolepsie , Neuropeptides , Narcolepsie/diagnostic , Narcolepsie/physiopathologie , Neuropeptides/liquide cérébrospinal , Neuropeptides/déficit , Neuropeptides/physiologie
SÉLECTION CITATIONS
Détails de la recherche